

Special Issue

Inflammatory Bowel Diseases: New Diagnostic and Therapeutic Approaches

Message from the Guest Editors

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are lifelong gastrointestinal tract disorders whose prevalence is projected to reach 1% by 2030. It is now evident that IBDs arise from a complex interplay of genetic, environmental, and microbial factors, leading to dysregulated immune responses. However, there are still several unresolved aspects that limit timely diagnosis and therapeutic options, impacting patients' prognosis and quality of life. Therefore, it is crucial to encourage research that addresses the existing knowledge gaps. In this Special Issue, we invite original research or review articles focused on various topics related to IBD, including:

- Mechanisms underlying IBD pathogenesis;
- Disease monitoring;
- Biomarkers;
- Pharmacological innovations (new targets and combination therapy);
- Endoscopic treatment;
- Risk stratification and individualized therapy;
- Management of extraintestinal manifestations;
- Comorbidities in patients with IBD

Guest Editors

Dr. Maria Manuela Estevinho

1. Department of Gastroenterology, Vila Nova de Gaia Espinho Hospital Center, Vila Nova de Gaia, Portugal
2. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal

Dr. Fernando Magro

1. Department of Gastroenterology, São João Hospital University Centre, Porto, Portugal
2. Unidade de Farmacologia Clínica, São João Hospital University Centre, Porto, Portugal
3. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal

Deadline for manuscript submissions

closed (31 March 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/175476

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).